Evaxion Secures Landmark AI-Discovered Vaccine Deal with MSD
Evaxion secured a major licensing deal for its AI-discovered vaccine, EVX-B3, with Merck & Co. (MSD), potentially worth over $600 million and validating Evaxion's groundbreaking AI platform.